Invention Grant
US09434947B2 Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome
有权
通过寡核苷酸调节KCNH2同种型表达作为长QT综合征的治疗方法
- Patent Title: Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome
- Patent Title (中): 通过寡核苷酸调节KCNH2同种型表达作为长QT综合征的治疗方法
-
Application No.: US14600958Application Date: 2015-01-20
-
Publication No.: US09434947B2Publication Date: 2016-09-06
- Inventor: Zhengfeng Zhou , Qiuming Gong , Matthew Stump
- Applicant: Zhengfeng Zhou , Qiuming Gong , Matthew Stump
- Applicant Address: US OR Portland
- Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
- Current Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
- Current Assignee Address: US OR Portland
- Agent Jeffrey M. Jackson
- Main IPC: C12N15/113
- IPC: C12N15/113
Abstract:
Oligonucleotides with activity in preventing poly(A) adenylation at intron 9 of the KCNH2 gene, as well as pharmaceutical compositions comprising the oligonucleotides and methods of using the oligonucleotides to treat long QT syndrome in a subject are disclosed. The oligonucleotides include antisense sequences corresponding to sites termed DSE-1 and DSE-2 in intron 9.
Public/Granted literature
Information query
IPC分类:
